NATIONAL INSTITUTES OF HEALTH
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeLeukemiaMyelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00101179
- Locations
- ๐บ๐ธ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
๐บ๐ธMount Sinai Hospital, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Erythroleukemia (M6a)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00101296
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1
Completed
- Conditions
- Childhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaChildhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Grade III Lymphomatoid Granulomatosis
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00101270
- Locations
- ๐บ๐ธ
COG Phase I Consortium, Arcadia, California, United States
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1
Terminated
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00101231
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
Phase 1
Terminated
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00101244
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase 1
Terminated
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00101088
- Locations
- ๐บ๐ธ
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 2
Completed
- Conditions
- Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Biological: recombinant interferon alfa-2bOther: laboratory biomarker analysis
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00101114
- Locations
- ๐บ๐ธ
Southwest Oncology Group, San Antonio, Texas, United States
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Localized Unresectable Adult Primary Liver CancerAdvanced Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerAdult Primary Hepatocellular CarcinomaRecurrent Adult Primary Liver CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT00101036
- Locations
- ๐บ๐ธ
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1
Completed
- Conditions
- Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral Astrocytoma
- Interventions
- Procedure: perfusion-weighted magnetic resonance imagingProcedure: diffusion-weighted magnetic resonance imagingOther: laboratory biomarker analysis
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00100880
- Locations
- ๐บ๐ธ
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Stage IV Breast CancerRecurrent Breast Carcinoma
- Interventions
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00100750
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States